Cholesterol metabolism and brain amyloidosis: Evidence for a role of copper in the clearance of Aβ through the liver

Current Alzheimer Research

Volumn 4, Issue 2, 2007, Pages 165-169

  Sparks, D Larry ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

ABCA1; AD like neuropathology; Amyloid beta; Liver copper; LRP

Indexed keywords

ABC TRANSPORTER A1; AMYLOID BETA PROTEIN; COPPER; HIGH DENSITY LIPOPROTEIN;

AMYLOID NEUROPATHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DISEASE COURSE; LIVER CLEARANCE; MALE; NONHUMAN; PRIORITY JOURNAL;

AMYLOID BETA-PROTEIN; AMYLOIDOSIS; ANIMALS; BRAIN; CHOLESTEROL; COPPER; LIVER; MALE; METABOLIC DETOXICATION, DRUG; RABBITS;

EID: 34147173784     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720507780362119     Document Type: Article

References (47)

1. Mahley RW. Apolipoprotein E: Cholesterol transport protein with expanded role in cell biology. Science 240:622-630 (1988).
2. Zerbinatti CV, G. B. LRP and Alzheimer's disease. Rev Neurosci 16:123-135 (2005).
3. Koldamova R, Staufenbiel M, Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem 280 (2005).
4. Koldamova RP, Lefterov IM, Ikonomovic MD, et al. 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J. Biol Chem 278 (15) (2003).
5. Deane R, Wu Z, Zlokovic BV. RAGE(yin) versus LRP(yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stoke (suppl 1)):2628-2631 (2004).
6. Deane R, Wu Z, Sagare A, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43(3):333-344 (2004).
7. Zarubica A, Trompier D, Chimini G. ABCA1, from pathology to membran function. Pflugers Arch 21:epub (2006).
8. Name N. Membrane proteins and phospholipids a effectors of reverse cholesterol transport. Biomed Khim 52:113-123 (2006).
9. Mahley RW, Huang Y, Weisgraber KH. Putting cholesterol in its place: ApoE and reverse cholesterol transport. J Clin Invest 116:1435-1442 (2006).
10. Sparks DL, Scheff SW, Hunsaker III JC, Liu H, Landers T, Gross DR. Induction of Alzheimer-like ß-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126:88-94 (1994).
11. Sparks DL. Dietary cholesterol induces Alzheimer-like ß-amyloid immunoreactivity in rabbit brain. Nutr Metab Cardiovasc Dis 7(3):255-266 (1997).
12. Sparks DL. Intraneuronal ß-amyloid immunoreactivity in the CNS. Neurobiol Aging 17(2):291-299 (1996).
13. Sparks DL, Schreurs BG. Trace amounts of copper in water induce β-amyloid plaques and learning deficits in a rabbit model of alzheimer's disease. Proc Natl Acad Sci USA 100(19):1065-1069 (2003).
14. Sparks DL, Friedland R, Petanceska S, et al. Trace Copper Levels in the Drinking Water, but not Zinc or Aluminum influence CNS Alzheimer-like Pathology. Journal of Nutrition, Health & Aging 10(4):247- (2006).
15. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 12(7):856-861 (2006).
16. Sparks DL, Sabbagh M, Connor D, et al. Statin therapy in Alzheimer's disease. Acta Neurol Scand (supp) 185:78-86 (2006).
17. Ghribi O, Larsen B, Schrag M, Herman MM. High cholesterol content in neurons increases BACE, B-amyloid, and phosphorylated tau levels in rabbit hippocampus. Experiment Neurol 200:460-467 (2006).
18. Ghribi O, Golvovko MY, Larsen B, Schrag M, Murphy EJ. Deposition of iron and B-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. J Neurochem (10.1111/j):1-12 (2006).
19. Durham RA, Parker CA, Emmerling MR, Bisgaier CL, Walker LC. Effect of age and diet on the expression of beta-amyloid 1-40 and 1-42 in the brains of apolipoprotein-E-deficient mice. Neurobiol Aging 19(4S):S281 (1998).
20. Shie FS, LeBoeuf RC, Leverenz JB, Jin LW. Effects of cholesterol feeding on histopathologic hallmarks of Alzheimer's disease in ??-amyloid precursor protein (APP) transgenic mice. Soc Neurosci 25:1859 (1999).
21. Li L, Zeigler S, Lindsey RJ, Fukuchi K. Effects of an atherogenic diet on amyloidosis in transgenic mice overexpressing the Cterminal portion of β-amyloid precurson protein. Soc Neurosci 25:1859 (1999).
22. Fishman CE, White SL, DeLong CA, et al. High fat diet potentiates β-amyloid deposition in the APP V717F transgenic mouse model of Alzheimer's disease. Soc Neurosci 25:1859 (1999).
23. Bales KR, Fishman C, DeLong C, Du Y, Jordan W, Paul SM. Dietinduced hyperlipidemia accelerates amyloid deposition in the APPv717f transgenic mouse model of Alzheimer's disease. Neurobiol Aging 21(1S):S139 (2000).
24. Refolo LM, Pappolla MA, Malester B, et al. Hypercholesterolemia accelerates Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7(4):321-331 (2000).
25. Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 5:890-899 (2001).
26. Petanceska SS, DeRosa S, Olm V, et al. Statin therapy for Alzheimer's Disease. Will it work? J Mol Neurosci 19:155-161 (2002).
27. Chauhan N, Siegel G, Feinstein D. Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain. Neurochem Res 29(10):1897-1911 (2004).
28. Sparks DL, Lochhead J, Horstman D, Wagoner T, Martin T. Water quality has a pronounced effect on cholesterol-induced accumulation of Alzheimer Amyloid β (Aβ) in rabbit brain. JAD 4:523-529 (2002).
29. DeMattos RB, Bales KR, Parsadanian M, et al. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 81(2):229-236 (2002).
30. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloi-beta efflux" A measure of brain amyloid burden in a mouse model of zlheimer's disease. Science 295:2264-2267 (2002).
31. Huang X, Cuajungco MP, Atwood CS, Moir RD, Tanzi RE, Bush AI. Alzheimer's disease, beta-amyloid protein and zinc. J Nutr 130(5S Suppl):1488S-1492S (2000).
32. Cuajungco MP, Goldstein LE, Nunomura A, et al. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem 275(26):19439-19442 (2000).
33. Moir RD, Atwood CS, Romano DM, et al. Differential effects of apolipoprotein E isoforms on metal-induced aggregation of A beta using physiological concentrations. Biochemistry 38(14):4595-4603 (1999).
34. Chen M, Durr J, Fernandez HL. Possible role of calpain in normal processing of beta-amyloid precursor protein in human platelets. Biochem Biophys Res Common 273(1):170-175 (2000).
35. White AR, Reyes R, Mercer JF, et al. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res 842(2):439-444 (1999).
36. Atwood CS, Scarpa RC, huang X, et al. Characterization of copper interactions with Alzheimer amyloid beta peptides: Identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem 75(3):1219-1233 (2000).
37. Sparks DL, Friedland R, Petanceska S, et al. Trace copper levels in drinking water, but not zinc or aluminum influence CNS Alzheimer'like pathology. J Nutr Health Aging 10:247-254 (2006).
38. Sparks DL, Hunsaker JC, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 11:601-607 (1990).
39. Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM, Poduslo JF. Pharmacokinetic analysis of the blood-brain barrier transport of 1251-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP, PS1) and its implications for amyloid plaque formation. J. Pharmacol Exp Ther 313(3):1370-1378 (2005).
40. Ghiso J, Shayo m, Calero M, et al. Systemic catabolism of Alzheimer's Abeta40 and Abeta42. J Biol Chem 279(44):45897-45908 (2004).
41. Hone E, Martins IJ, Fonte J, Martins RN. Apolipoprotein E influences amyloid-beta clearance from the murine periphery. J Alzheimers Dis 5(1):1-8 (2003).
42. Tamaki C, Ohtsuki S, ,, Iwatsubo T, et al. Major Involvement of Low-Density Lipoprotein Receptor-Related Protein 1 in the Clearane of Plasma Free Amyloid beta-Peptide by the liver. Pharm Res 23(7):1407-1416 (2006).
43. Sparks DL, Petanceska S, Sabbagh M, et al. Cholesterol, copper and Aβ in controls, MCI, AD and the AD Cholesterol-Lowering Treatment trial (ADCLT). Curr Alz Res 2:527-539 (2005).
44. Zan ZX, Papadopoulos V. Function of beta-amyloid in cholesterol transport: A lead to neurotoxicity. FASEB J 16:1677-1679 (2002).
45. Harris-White ME, Frautschy SA. Low density lipoprotein receptro-related troteins (LRPs), Alzheimers and cognition. Curr Drug Targets CNS Neurol disord 5:469-480 (2005).
46. Hone E, Martins IJ, Jeoung M, Ji TH, Gandy S, Martins RN. Alzheimer's disease amyloid-beta peptide modulates apolipoprotein E isoform specific receptor binding. J Alzheimers Dis 7:315-317 (2005).
47. Wilson LM, Pham CL, Jenkins AJ, et al. High density lipoproteins bind Abeta and apoliporotein C-II amyloid fibrils. J Lipid Res 47:755-760 (2006).